Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
961-980 of 3,900 trials

Recurrent Diverticulitis: MBK-01 Capsules

We are studying whether MBK-01, a new intestinal microbiota capsule, can help reduce episodes of recurrent diverticulitis. The trial will also assess its safety and find the best dosage for patients.

Acute Diverticulitis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesGastroenterology

Cystectomy Complications: Antifungal Treatment Study

We are testing whether a new antifungal medication can help reduce complications after radical cystectomy. This study compares the medication to a placebo to see if it makes a difference.

Fungal Infection3-6 monthsMonitoring phase (IV)Standard MedicinesInfectious DiseasesUrology

Advanced Solid Tumors: ABBV-400 Treatment

We are evaluating a new treatment for individuals with advanced solid tumors to see how safe it is and if it may help improve their condition.

Locally Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Internal MedicineOncology

Advanced Solid Tumors: Testing IPN01194

We are studying a new drug, IPN01194, for adults with advanced solid tumors to see how safe it is and how well it works. This trial aims to understand its effects when used alone.

MelanomaPancreatic Ductal AdenocarcinomaColorectal Cancer≤3 monthsSafety phase (I)Efficacy phase (II)No PlaceboCost ReimbursementOncology

Herpes-Zoster Vaccine: Impact on Patients with Inflammatory Rheumatic Diseases

We are studying how anti-rheumatic treatments influence the effectiveness of the herpes-zoster vaccine in patients with inflammatory rheumatic diseases. This research aims to see if the vaccine provides adequate protection against shingles.

Inflammatory Rheumatic DiseasesVaccinationMonitoring phase (IV)Infectious DiseasesRheumatology

Becker Muscular Dystrophy: EDG-5506 Treatment Study

We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.

Becker's Muscular Dystrophy>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Clostridioides difficile Infection: EXL01 Treatment

We are studying a new oral treatment, EXL01, to see if it can help prevent the return of Clostridioides difficile infection in high-risk patients. The trial will evaluate its safety and effectiveness, along with its impact on digestive health and quality of life.

Recurrent Clostridioides difficile Infection>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesGastroenterologyInfectious Diseases

Limited-Stage Small-Cell Lung Cancer: Tarlatamab Study

We are studying whether tarlatamab can improve survival and prevent disease progression in patients with limited-stage small-cell lung cancer after chemoradiation therapy. Participants will receive either tarlatamab or a placebo to compare their effects.

Limited-Stage Small-Cell Lung CancerConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Multiple Myeloma: Linvoseltamab Therapy Study

We are examining a new treatment called Linvoseltamab for adults with multiple myeloma that hasn't responded to standard care. The study looks at how it works with other cancer treatments.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Bladder Cancer: Erdafitinib Delivery System Study

We are testing a new way to deliver Erdafitinib for people with non-muscle-invasive or muscle-invasive bladder cancer. The goal is to see how safe it is and how well it works compared to standard treatments.

Localized Bladder Cancer>2 yearsSafety phase (I)OncologyUrology

B-cell Non-Hodgkin Lymphoma: JNJ-90014496

We are testing a new treatment called JNJ-90014496 for adults with B-cell Non-Hodgkin Lymphoma. The goal is to see how well it works and its safety compared to existing options.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Oncology

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Optimizing Drug Levels

We are studying how blood levels of heart failure medications affect patient health. This research may help improve treatment plans for individuals with heart failure.

Chronic Heart Failure with Reduced Ejection Fraction>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology

Obesity in Adolescents: Semaglutide Treatment Study

We are exploring whether a weekly injection of semaglutide can help adolescents with obesity lose weight more effectively than a placebo. This study also looks at the safety and overall health impacts of the treatment.

Obesity1-2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Postoperative Pain Management After Cardiac Surgery: NSAIDs Study

We are investigating whether nonsteroidal anti-inflammatory drugs can help reduce pain after cardiac surgery. This study will also look at how these medications affect recovery and overall quality of life.

Postoperative Pain After Cardiac Surgery>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine